让“中国创新”惠及全球 ——访阿斯利康中国总经理林骁

Group 1 - The Chinese pharmaceutical industry is entering an innovative development phase, providing more motivation and assurance for AstraZeneca's innovation in China [1] - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in Beijing, aiming to enhance "China innovation" for global benefit [1] - AstraZeneca has two of its six global strategic R&D centers located in China, with a total R&D team exceeding 1,000 people, reflecting the company's commitment to the Chinese market [1] Group 2 - AstraZeneca has signed a strategic R&D cooperation agreement with China National Pharmaceutical Group, focusing on AI-driven drug research [2] - The company has established a $550 million fund to invest in local biopharmaceutical companies, having invested in 27 local enterprises [2] - AstraZeneca plans to introduce 20 new global drugs in China by 2030, having already brought over 40 innovative drugs to the market in the past 30 years [2] Group 3 - AstraZeneca is committed to promoting early diagnosis and treatment, addressing challenges faced by patients in rural areas [3] - The company has engaged with approximately 400 cities and 2,800 counties in China to ensure innovative drugs and quality medical resources reach more patients [3]